Anatomic and Clinical Pathology Characterization of Drug-Induced Sinusoidal Obstruction Syndrome (Veno-Occlusive Disease) in Cynomolgus Macaques
| Autor: | Rebecca Kohnken, Hadi Falahatpisheh, Magali Guffroy, Kyathanahalli S Janardhan |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Liver injury
Pathology medicine.medical_specialty Pathology Clinical Reticulin stain Clinical pathology business.industry CD34 Hepatic Veno-Occlusive Disease Endothelial Cells Cell Biology Toxicology medicine.disease Pathology and Forensic Medicine Macaca fascicularis Sinusoid Fibrosis medicine Immunohistochemistry Animals Platelet business Molecular Biology |
| Zdroj: | Toxicologic pathology. 50(1) |
| ISSN: | 1533-1601 |
| Popis: | Sinusoidal obstruction syndrome (SOS) is a unique form of liver injury that occurs after exposure to chemotherapeutic drugs and toxins. The diagnosis of SOS in humans remains a challenge as the clinical criteria have low specificity and there are no reliable noninvasive biomarkers. The mechanism of injury is believed to be damage to liver endothelial cells, primarily sinusoidal endothelial cells (SECs), which leads to sinusoidal dilation, central venous fibrosis, and/or nodular regeneration. Nonclinical data suggest that this uncommon liver toxicity can be recapitulated in cynomolgus monkeys, and it is critical that pathologists are familiar with its characteristic clinicopathologic features. Elevations in liver enzymes, in particular aspartate aminotransferase, associated with isolated thrombocytopenia, should raise the suspicion of SEC injury for specific drug classes. Characterization of liver microscopic findings in monkeys benefits from the use of appropriate stains, such as reticulin stain, and VEGFR2 and CD34 immunohistochemical (IHC) stains. CD41 IHC demonstrates platelet accumulation in injured sinusoids, the likely cause of thrombocytopenia commonly reported in SOS. In conclusion, this report provides a comprehensive characterization of the pathology findings of drug-induced SOS in monkeys with the objectives of ensuring appropriate nonclinical recognition of the liability and informing clinical development strategy and monitoring. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|